Physician profile
Thomas E Kingston
NPI 1790744597
$3,693.17
in general payments reported to CMS, 2019-2025
27 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $1,006 · 2021: $149 · 2022: $145 · 2023: $42.83 · 2024: $136 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.67 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $716.51 | 2019-2023 | Xtandi |
| Boston Scientific Corporation | $326.25 | 2019-2025 | General - Erectile Dysfunction, Lithovue |
| Teleflex LLC | $272.02 | 2021-2025 | Barrigel |
| Janssen Biotech, INC. | $262.17 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $235.67 | 2019-2024 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $232.61 | 2019-2020 | |
| Abbvie INC. | $198.80 | 2019-2020 | |
| Pfizer INC. | $187.05 | 2019-2020 | |
| Antares Pharma, INC. | $159.50 | 2019-2020 | |
| Allergan, INC. | $140.48 | 2019-2020 | |
| Travere Therapeutics, INC. | $136.63 | 2019-2020 | |
| Neotract INC. | $117.66 | 2019-2020 | |
| Calyxo, INC. | $116.79 | 2025 | Cvac Aspiration System |
| Endo Pharmaceuticals INC. | $88.51 | 2019-2020 | |
| Therapeuticsmd, INC. | $71.16 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $59.61 | 2019-2020 | |
| 180 Medical, INC. | $57.33 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $54.93 | 2019 | |
| Urovant Sciences INC | $46.80 | 2022 | |
| Blue Earth Diagnostics | $44.17 | 2019 | |
| Rochester Medical Corporation | $35.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Dendreon Pharmaceuticals LLC | $26.59 | 2019 | |
| Amgen INC. | $25.02 | 2020 | |
| Urogen Pharma, INC. | $18.16 | 2025 | |
| Acerus Pharmaceuticals Corporation | $16.02 | 2020 | |
| Myriad Genetic Laboratories, INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kingston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.